Plant Biotech Firm Venganza Secures US Patent on RNAi Technology | GenomeWeb

Plant biotechnology firm Venganza hit a major milestone last week, receiving a US patent on its core technology, which is based on the use of RNAi to create pest and pathogen resistance in crop plants.

With this key piece of intellectual property in hand, the company is now in the process of negotiating licenses to its technology with unnamed “major” companies working in the space, Venganza President Charles Niblett told Gene Silencing News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.